FDA Recall Paliperidone

View Recall Number, Date, Reasons, Quantity

FDA Recall Enforcement Reports

The last Recall Enforcement Report for Paliperidone with NDC 0591-3692 was initiated on 08-06-2018 as a Class II recall due to defective delivery system: there is a potential for some tablets to be missing the laser drilling which might affect drug release. The latest recall number for this product is D-0096-2019 and the recall is currently terminated as of 02-13-2020 .

Recall Number Initiation Date Report Date Recall Classification Product Quantity Product Description Status
D-0096-201908-06-201810-31-2018Class II27,816 bottlesPaliperidone Extended Release Tablets 3 mg, packaged in a) 30-count bottle(NDC 0591-3693-30), b) 90-count bottle (NDC-0591-3693-19), Rx only, Manufactured by: Actavis Laboratories FL, Inc., Fort Lauderdale, FL 33314, Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054Terminated
D-0097-201908-06-201810-31-2018Class II3,785 bottlesPaliperidone Extended Release Tablets 9 mg, packaged in a) 30-count bottle(NDC 0591-3695-30) , b) 90-count bottle (NDC 0591-3695-19), Rx only, Manufactured by: Actavis Laboratories FL, Inc., Fort Lauderdale, FL 33314, Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054Terminated
D-0960-201705-31-201707-19-2017Class I360 bottlesPaliperidone Extended-Release Tablets, 3 mg, 90 count bottles, Rx only, Manufactured by: Actavis Laboratories FL, Inc., Fort Lauderdale, FL 33314 USA Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054, USA, NDC: 0591-3693-19Terminated

What is the Enforcement Report?

All drug recalls are monitored by the Food and Drug Administration (FDA) and are included in the Enforcement Report once they are properly classified. The FDA will determine if a firm's removal or correction actions of a marked product meet the requirements to be considered a "recall". The FDA will also determine the public hazard assessment and a recall classification will be published in the Enforcement Report.